- Home
- TLRY vs EVMN Comparison
TLRY vs EVMN Comparison
Compare TLRY & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | EVMN |
|---|---|---|
| Founded | N/A | 2020 |
| Country | Canada | United States |
| Employees | N/A | 48 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 914.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLRY | EVMN |
|---|---|---|
| Price | $5.58 | $22.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $72.33 | $43.88 |
| AVG Volume (30 Days) | ★ 6.8M | 260.8K |
| Earning Date | 04-01-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.79 | N/A |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $13.89 |
| 52 Week High | $15.70 | $33.20 |
Technical Indicators
Market Signals| Indicator | TLRY | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 41.03 |
| Support Level | $1.00 | $21.14 |
| Resistance Level | $7.01 | $25.50 |
| Average True Range (ATR) | 0.53 | 1.78 |
| MACD | -0.12 | -0.41 |
| Stochastic Oscillator | 2.72 | 10.37 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.